This article is more than 5 years old. Information may no longer be current.
Endovascular therapy effective in aortoiliac lesions at 1 year
Click Here to Manage Email Alerts
In a real-world population of patients with aortoiliac lesions, endovascular therapy was safe and effective, according to a research letter published in Circulation: Cardiovascular Interventions.
The researchers analyzed 893 patients (mean age, 73 years; 83% men) with peripheral artery disease from the OMOTENASHI registry who underwent endovascular therapy, or EVT, for 1,128 limbs with aortoiliac lesions between April 2014 and April 2016.
At baseline, 42% of patients were Rutherford class 2 and 51% were Rutherford class 3, whereas 36% of limbs had chronic total occlusion.
At 30 days, 0.9% of patients had a major adverse event, defined as death, MI, stroke or target vessel revascularization, Yasutaka Yamauchi, MD, PhD, from Cardiovascular Center, Takatsu General Hospital, Kanagawa, Japan, and colleagues wrote.
For the 631 limbs available for analysis at 1 year, the estimated primary patency rate was 86.2% (95% CI, 83.3-89.2).
The Kaplan-Meier estimate of 1-year freedom from TVR was 98.4% (95% CI, 97.6-99.2), Yamauchi and colleagues wrote.
In addition, the Kaplan-Meier estimate of 1-year overall survival was 97% (95% CI, 95.8-98.2) and the Kaplan-Meier estimate of 1-year freedom from MACE, defined as death, MI or stroke, was 96.2% (95% CI, 94.9-97.5).
The researchers also analyzed six health-related quality of life outcomes and found that all six improved between baseline and 1 year (P < .001 for all).
“These 1-year results of our ongoing prospective multicenter study indicate that EVT shows acceptable safety and efficacy in patients with aortoiliac lesions ... supporting the recent recommendation that EVT can be a first-line treatment for aortoiliac disease,” Yamauchi and colleagues wrote. “To confirm the long-term safety and efficacy of EVT, the 3-year OMOTENASHI registry results are awaited.” – by Erik Swain
Disclosures: The authors report no relevant financial disclosures.
Click Here to Manage Email Alerts